A Phase II Double-Blind Randomized Study of the Simultaneous Administration of Recombinant Human Interleukin-6 and Recombinant Human Granulocyte Colony-Stimulating Factor Following Paclitaxel and Carboplatin Chemotherapy in Patients with Advanced Epithelial Ovarian Cancer

By Hochster H.   Speyer J.L.   Mandeli J.P.   Runowicz C.   Wadler S.   Berk G.   Wallach R.   Holland J.F.   for the New York Gynecologic Oncology Group  

Gynecologic Oncology, Vol. 72, Iss. 3, 1999-03 ,pp. : 292-297

Elsevier

Access to resources Recommend Favorite

Combined Carboplatin plus Ifosfamide and Cisplatin in Patients with Advanced Ovarian Carcinoma. A Phase I-II Study

By Lorusso V.   Leone B.   Di Vagno G.   Manzione L.   Palmeri S.   Vallejo C.   Machiavelli M.   Nacci G.   Bilancia D.   Leonardi V.   Catino A.   Gargano G.   Loverro G.   Selvaggi L.   De Lena M.  

Gynecologic Oncology, Vol. 68, Iss. 2, 1998-02 ,pp. : 172-177

Elsevier

Access to resources Recommend Favorite

A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma

By Yeo W.   Leung T.W.T.   Chan A.T.C.   Chiu S.K.W.   Yu P.   Mok T.S.K.   Johnson P.J.  

European Journal of Cancer, Vol. 34, Iss. 13, 1998-12 ,pp. : 2027-2031

Elsevier

Access to resources Recommend Favorite

Phase II Trial of Topotecan, Carboplatin, and Paclitaxel as Front-Line Therapy in Suboptimal Advanced Epithelial Ovarian Cancer

By Bolis G.   Scarfone G.   Villa A.   Parazzini F.  

Gynecologic Oncology, Vol. 81, Iss. 2, 2001-05 ,pp. : 331-333

Elsevier

Access to resources Recommend Favorite

A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: Neurological toxicity and quality-of-life evaluation

By                  

International Journal of Oncology, Vol. 40, Iss. 3, 2012-01 ,pp. : 773-781

Spandidos Publications

Access to resources Recommend Favorite